Although some phase I/II clinical trial explored the application of dacomitinib in uncommon mutations [11, 12], there is limited evidence for dacomitinib treating advanced NSCLC patients with uncommon EGFR mutations in a real-world setting. Here, EGFR is linked to non-small cell lung carcinoma.